Skip to main content

Versameb raises 6.4 million Swiss francs

| News

Versameb raises 6.4 million Swiss francs


Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform. Versameb was supported by the healthcare accelerator program BaseLaunch of in 2017/18.

Biotech (img: angellodeco/shutterstock)

With its latest financing round, Versameb has raised 11.8 million Swiss francs in total capital to date. “We are very pleased and grateful to see the interest of new investors, as well as the strong confidence shown by our existing shareholders,” Friedrich Metzger, CEO of Versameb, said in a press release.

The Basel-based biopharmaceutical has developed a technology platform that enables “efficient development of functional mRNA molecules for customized protein expression and modification in various therapeutic indications”.

The proceeds of this financing round will now be used to expand the platform, called VERSagile, in multiple indications and advance “the lead program towards clinical studies”.

Versameb also announced recent personnel changes. Reinhard Ambros was elected to the board of directors and subsequently appointed chairman, succeeding Roger Meier. According to the press relase, Ambros has helped to build the Novartis Venture Fund into a leading corporate biotech venture fund.

“I was attracted to join Versameb because I see a great potential in its unique mRNA technology platform and the ambitious goals to develop next-generation RNA therapies,” Ambros said.

In addition, Versameb recently appointed Isabel Ferreira as Chief Business Officer, where she will be responsible for leading the company’s global partnering and corporate development strategy. Prior to joining Versameb, she was the director of global business development at Roche Partnering.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.